| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Cellular Defense and Carcinogenesis Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, Maryland
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Ligands of the AhR include several classes of environmental carcinogens, including polyhalogenated biphenyls such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), aryl hydrocarbons such as benzo(a)pyrene, and heterocyclic amines such as 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. These classes of xenobiotics are all suspected human carcinogens. For example, TCDD, a widespread environmental contaminant generated by a variety of industrial processes, has been linked to an increase in many types of human cancers, including hepatocellular cancer (3 , 4) . In animal models, TCDD has been shown to cause acute toxicity (5) , increased oxidative stress (6) , impaired ovulation (7) , and immunotoxicity (8) . These effects in animal models are believed to closely reflect the deleterious effects of TCDD in humans (9) . TCDD has the highest affinity for the AhR of any known compound, and is considered the prototypical AhR ligand. Its interaction with the AhR is essential to its toxicity, as demonstrated in AhR-knockout mice, which are impervious to TCDD exposure (10) .
Because of the central role of the AhR in the toxicity of TCDD and genotoxicity of numerous xenobiotics, the development of inhibitors of AhR-mediated signal transduction has been an important goal of chemoprevention science. In the present study, we have examined the effects of the salicylates on the AhR and the metabolic pathway it regulates. Salicylic acid was first identified in willow bark extracts as an active anti-inflammatory compound more than 200 years ago, and its synthetic derivative, acetylsalicylic acid (aspirin), has be used to treat a number of human maladies for over a century. Recent studies have demonstrated that salicylate usage is associated with a reduction of incidence of several types of cancer (11, 12, 13) , and animal studies have shown that salicylates are potent inhibitors of chemically induced carcinogenesis (14 , 15) . We have, therefore, examined the effects of salicylates on the AhR function in HepG2 cells, a well-differentiated human liver cancer cell line that has been extensively used as a model system to study the AhR (16, 17, 18, 19) . We demonstrated that the synthetic salicylate, salicylamide (SAL), is a potent and long-lasting inhibitor of TCDD-induced signal transduction mediated by the AhR.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Cell Culture.
HepG2 human hepatoma cells were grown with RPMI 1640 supplemented with 2 mM glutamine and 10% fetal bovine serum in a 5% CO2 humidified incubator at 37°C. For all of the treatment compounds, DMSO was used as the vehicle and did not exceed 0.1%.
Carcinogen Activation Capacity in HepG2 Cells.
The ability of SAL to affect CYP enzyme activity was evaluated in intact cells by measurement of ethoxyresorufin-O-deethylase (EROD) activity. In 24-well plates, HepG2 cells were incubated with increasing concentrations of salicylates in the presence of 1 nM TCDD for 24 h, for dose-response experiments. For time course experiments, cells were incubated with increasing concentrations of SAL, or with other test compounds at concentrations that inhibit 50% (IC50), in the presence of 1 nM TCDD for various times from 6 to 144 h. Medium was decanted, and cells were washed once with PBS. Medium containing 5 µM ethoxyresorufin was added. Increasing fluorescence as a result of the conversion of ethoxyresorufin to resorufin by CYP enzymes was measured using a CytoFluor multiwell plate reader (Applied Biosystems, Foster City, CA), with an excitation of 530 nm and emission at 590 nm. The reaction was allowed to run for 30 min.
Reverse Transcription-PCR.
In 6-well plates, cells were treated with various concentrations of SAL alone, or with 100 pM TCDD, for 8 h. Cells were washed twice with PBS, and total RNA was isolated with TRIzol reagent per manufacturer’s instructions. cDNA was synthesized from 2 µg of total RNA using an Omniscript kit according to the manufacturer’s instructions. Semiquantitative reverse transcription-PCR for cytochrome P4501A1 (CYP1A1), cytochrome P4501A2 (CYP1A2), and cytochrome P4501B1 (CYP1B1) expression was performed as described previously (20)
. Primer sequences and conditions for CYP1A1 and CYP1B1 were as described by Dohr et al. (21)
, and for cytochrome P4501A2 (CYP1A2) as described by Chung and Bresnick (22)
. Primers for glyceraldehyde-3-phosphate dehydrogenase were from Clontech (Palo Alto, CA). The optimum cycle number that fell within the exponential range of response for CYP1A1 (23 cycles), CYP1A2 (28 cycles), CYP1B1 (30 cycles) and glyceraldehyde-3-phosphate dehydrogenase (17 cycles) was used. The level of CYP mRNA was normalized to the level of glyceraldehyde-3-phosphate dehydrogenase mRNA.
Luciferase Assay.
HepG2 cells were seeded onto 6-well plates at 400,000 cells/well. After 24 h, the cells were transiently transfected with a luciferase reporter vector (1.5 µg/well) containing three repeats of the XRE and a ß-galactosidase vector (pCMV-ß-gal; 0.6 µg/well) with the use of LipofectAMINE. Transfected cells were treated with various concentrations of salicylates in the presence of 10 nM TCDD. Luciferase activity was measured using a Microlumat LB 96P luminometer (EG&G Berthold). ß-galactosidase activity was determined by the method of Rosenthal (23)
.
Electrophoretic Mobility Shift Assay.
HepG2 cells were incubated with DMSO (0.1%), 10 nM TCDD alone, or 10 nM TCDD with 1 mM SAL for 2 h at 37°C. Nuclear protein was isolated, and electrophoretic mobility shift assay was performed by the method of Denison et al. (24)
. Synthetic oligonucleotides containing the AhR-binding site of the XRE (forward primer, 5'-GAT CTG AGC TCG GAG TTG CGT GAG AAG AGC CG-3'; reverse primer, 5'-CGG CTC TTC TCA CGC AAC TCC GAG CTC AG-3'; Ref. 25
) were labeled with [32P]dCTP. Binding reactions were performed for 25 min (10-min preincubation without probe + 15-min incubation with probe) at room temperature and contained 10 µg of nuclear protein, 2 µg of polydeoxyinossinic deoxycytidylic acid and labeled probe (
50,000 cpm) in a final volume of 20 µl of binding buffer [25 mM Tris-HCl (pH 7.9), 50 mM KCl, 1 mM MgCl2, 1.5 mM EDTA, 0.5 mM DTT, 5% (v/v) glycerol]. To determine the specificity of binding to the oligonucleotide, excess unlabeled specific probe was incubated with the nuclear extract of TCDD-treated cells for 15 min. DNA–protein complexes were separated under nondenaturing conditions on a 6% (w/v) polyacrylamide gel with 0.5x Tris/borate/EDTA running buffer. The gels were dried, and the amount of labeled probe present in the DNA–protein complexes was determined with a Bio-Rad GS-363 molecular imaging system.
Ligand-Binding Assay.
AhR ligand binding was measured according to the methods of Raha et al. (26)
. Cytosolic protein (1.5 mg/500 µl) was incubated with 20 nM [3H]TCDD in the presence of DMSO (5 µl/500 µl), 5 mM SAL, or 10 µM TCDD (unlabeled) for 2 h at 4°C. Samples were centrifuged in linear gradients of 5–30% sucrose (v/v) in 12 ml of Beckman Quick-Seal rotor tubes at 65,000 rpm for 2 h at 4°C in a Beckman VTI-65–1 rotor. Fractions (500 µl each) of the gradients were collected, and radioactivity was determined by scintillation counting.
Statistical Analysis.
Statistical analyses were performed with STATVIEW Statistical Analysis Software (SAS Institute, San Francisco, CA). Differences between group mean values were determined by a one-factor ANOVA, followed by Fisher’s protected least significant difference post hoc analysis for pairwise comparison of means. A two-sided P value of <0.05 was considered significant. CYP mRNA levels in Figs. 3
and 4
are shown on a linear scale.
|
|
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The cellular capacity for enzymatic activation of procarcinogens was measured by EROD assay. Treatment of HepG2 cells with 1 nM TCDD resulted in an increase in EROD-specific activity from nondetectable levels to 17 pmol/min/well in controls (Fig. 2A)
. The addition of SAL caused a concentration-dependent inhibition of EROD activity, with an interpolated IC50 of 170 µM. SAL at 1 mM suppressed EROD levels to 10% of cells treated with TCDD alone. In contrast, both aspirin and salicylic acid had no inhibitory effect at any concentration (Fig. 2A)
. TCDD caused a persistent increase in EROD activity in HepG2 cells that remained at maximal levels for 6 days (Fig. 2B)
. SAL, added along with TCDD, caused an inhibition of enzyme activity that persisted throughout the 6-day time course, regardless of the concentration used (Fig. 2B)
.
|
|
-naphthoflavone (a positive control) inhibited EROD activity by 84%, compared with controls (Table 1)
. SAL (250 µM) was also added to microsomes isolated from TCDD-treated HepG2 cells, and EROD activity was assayed. There was no significant effect on microsomal EROD activity (P = 0.70; Table 1
), whereas -naphthoflavone completely abolished EROD activity.
|
. SAL treatment alone had no effect on basal CYP expression (Fig. 3B)
. Aspirin did not have an effect on TCDD-induced CYP mRNA (data not shown).
Effect of Salicylates on XRE-Controlled Luciferase Reporter Activity.
HepG2 cells were transiently transfected with a luciferase reporter vector containing multiple copies of the XRE. TCDD induced luciferase activity by 45-fold above control levels. The addition of SAL resulted in a concentration-dependent decrease of luciferase activity (Fig. 4)
. Aspirin and salicylic acid had no effect (Fig. 4)
.
Effect of SAL on AhR Activation.
The effect of SAL on TCDD-induced activation of the AhR was measured by electrophoretic mobility shift assay. TCDD (10 nM) caused a significant increase in AhR translocation to the nucleus and in binding to the XRE. This was completely suppressed in cells cotreated with 1 mM SAL (Fig. 5)
. The specificity of the bandshift was confirmed by treatment of nuclear extracts with excess unlabeled XRE and by incubation with an antibody to the AhR, which abolished AhR-XRE binding (data not shown), as we have demonstrated previously (27)
.
|
.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The toxicity of TCDD and other dioxins have, as a result, been intensely studied. Animal experimentation has demonstrated that, based on the minimal effective carcinogenic dose, TCDD is the most potent animal carcinogen yet discovered (31) . There is mounting experimental evidence suggesting that TCDD may affect human fertility, because it is associated with anovulation and dysfunctional spermatogenesis in primates and other animals (32, 33, 34, 35) . Developmental anomalies in infants may arise as a result of exposure via breast milk (36) . Epidemiological studies have indicated that TCDD exposure is associated with an increase in many types of cancer, including lung, liver, and rectal cancers (3) . TCDD has also been linked to increased ischemic heart disease (37 , 38) .
Given the ubiquity of TCDD contamination and its adverse impact on human health, the mechanisms of TCDD toxicity are of great interest. TCDD does not bind DNA, which indicates that it is not directly genotoxic. The primary mechanism of biological damage by TCDD has been reported to be the generation of reactive oxygen species (39, 40, 41) . This occurs as a consequence of CYP enzyme activity. A postulated mechanism for this is the auto-oxidation of the cytochrome P-450 mono-oxygenase complex, which generates superoxide (40) . Superoxide can spontaneously dismutate, liberating hydrogen peroxide as a byproduct, which, in the presence of transition metals, can produce hydroxy radicals, leading to indiscriminate damage to cellular biomolecules, including DNA. This hypothesis is consistent with the observation that the deleterious effects of TCDD are dependent on the AhR. The basal expression of CYP is very low. Only after ligands of the receptor, such as TCDD, activate the AhR, does the expression of CYP1A1 (as well as CYP1A2 and CYP1B1) increase. This AhR-dependent mechanism has been demonstrated in AhR-null mice, which do not up-regulate CYP expression when challenged with TCDD and are unaffected by TCDD, even at doses that are 10 times higher than that which induces severe toxic and pathological effects in wild-type mice (10) .
Inhibition of AhR-mediated signal transduction would, therefore, prevent TCDD-induced biological damage. We, and others, have described natural and synthetic compounds that act in this regard, e.g., the synthetic flavonoid -naphthoflavone acts antagonistically by competing with TCDD for binding of the AhR (42)
. However, by themselves, these compounds act as agonists, activating the AhR, resulting in an increase in CYP1A1 expression. Our laboratory has recently characterized several naturally occurring phytochemicals that act in this dual manner (43, 44, 45)
. The AhR is a promising molecular target, and a pure antagonist of the AhR would be potentially therapeutic for the prevention of human diseases that result from both acute and chronic TCDD exposure. In the present study, we have examined three members of the salicylate family for their effects on the AhR. These include salicylic acid, acetylsalicylic acid (aspirin), and SAL, a natural phytochemical and two synthetic derivatives of salicylic acid, respectively (for structures see Fig. 1
). These compounds have important advantages, being relatively inexpensive, and more importantly, they have already been used extensively in humans. Furthermore, SAL is commercially available in many pain remedy preparations and is often prescribed for patients with aspirin sensitivity.
There was a concentration-dependent decrease in TCDD-induced CYP enzyme activity, as measured by EROD assay, in HepG2 cells cotreated with SAL, but not in HepG2 cells cotreated with aspirin or salicylic acid (Fig. 2A)
. There is a sustained increase in EROD activity upon the addition of TCDD, because, unlike other ligands of the AhR such as benzo(a)pyrene, TCDD is not metabolized by CYPs and is, thus, available to chronically activate the receptor. A single cotreatment with SAL permanently inhibited this increase in a concentration-dependent manner (Fig. 2B)
. The inhibitory effect of SAL on CYP enzyme activity is, thus, long-lived. This is in contrast to the actions of other well-known inhibitors of CYP activity, such as resveratrol, -naphthoflavone, dibenzoylmethane, curcumin, and quercetin. The inhibitory effects (at IC50 concentrations) of these compounds rapidly decline, presumably because they are metabolized by the cells, and they are completely ineffective in abolishing TCDD-induced EROD activity after 48 h of incubation (data not shown). Therefore, SAL is the only compound identified thus far that produces a sustained inhibition of TCDD-induced CYP enzyme activity.
Two possible mechanisms may account for the inhibitory action by SAL. First, SAL could directly bind to the CYP enzymes and inhibit their activity. However, when cells were pretreated with TCDD to induce CYP activity, SAL treatment was ineffective (Table 1)
. Furthermore, SAL added to microsomes isolated from TCDD-treated cells also had no effect on CYP activity (Table 1)
. These results indicate that SAL does not directly affect CYP enzyme activity. We, therefore, hypothesized that the effect of SAL was at the level of CYP expression. The effect on mRNA levels was investigated by reverse transcription-PCR, which demonstrated that CYP1A1, CYP1A2, and CYP1B1 induction by TCDD was completely blocked in cells cotreated with SAL (Fig. 3A)
, but SAL treatment alone did not affect basal CYP expression (Fig. 3B)
. This is in contrast to some other inhibitors of induced CYP expression, such as dibenzoylmethane (43)
, galangin (44)
, and curcumin (45)
, that act as agonists when administered alone. Because CYP expression is regulated by XREs, we evaluated the effect of SAL on XRE-driven luciferase activity as a measure of transcription. SAL suppressed the up-regulation of XRE-controlled transcription by TCDD in a concentration-dependent manner, whereas aspirin and salicylic acid, consistent with the lack of effect on EROD activity, had no effect (Fig. 4)
. The reason that salicylic acid and aspirin are ineffective, despite their structural similarity to SAL, is not known.
We used gel-shift assays to further determine whether SAL affected the binding of activated (ligand-bound) AhR to XREs present in the promoter regions of CYP genes. As shown in Fig. 5
, SAL inhibited the binding of the TCDD-activated AhR to the XRE. We concluded from this that the decrease in TCDD-stimulated transcription and mRNA levels caused by SAL (Figs. 3
and 4)
was caused by preventing the activation of the AhR to its DNA-binding form. This could occur as a result of inhibiting the binding of the ligand to the receptor, which was confirmed by ligand-binding assay. We demonstrated that SAL substantially reduced the binding of TCDD to the cytosolic AhR (Fig. 6)
. Although the inhibition was not completely blocked, this was most likely caused by the high levels (20 nM) of [3H]-TCDD necessary to elicit detectable binding in this assay system (46)
.
This is the first demonstration of SAL as a potent inhibitor of the AhR that, as a result, can block signal transduction initiated by TCDD exposure. It is, furthermore, a pure antagonist of the AhR, unlike most other AhR inhibitors that have been characterized in this laboratory and others. Unlike several other compounds that directly bind and inhibit CYP enzyme activity, it is exceptionally long-lasting. Finally, SAL has already been extensively used in humans; therefore, its safety and pharmacokinetics are already well established. SAL may, therefore, serve as a promising chemopreventive compound that targets the AhR.
|
FOOTNOTES |
|---|
Requests for reprints: Grace Chao Yeh, Basic Research Laboratory, Building 538/Room 141, National Cancer Institute-Frederick, Frederick, MD 21702-1201. Phone: (301) 846-5369; Fax: (301) 846-6395;Email: yeh{at}ncifcrf.gov
Received 4/10/03. Revised 9/23/03. Accepted 9/29/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  C. J. MacDonald, R. Y. S. Cheng, D. D. Roberts, D. A. Wink, and G. C. Yeh Modulation of Carcinogen Metabolism by Nitric Oxide-Aspirin 2 Is Associated with Suppression of DNA Damage and DNA Adduct Formation J. Biol. Chem., August 14, 2009; 284(33): 22099 - 22107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Khuda-Bukhsh, S. S. Bhattacharyya, S. Paul, S. Dutta, N. Boujedaini, and P. Belon Modulation of Signal Proteins: A Plausible Mechanism to Explain How a Potentized Drug Secale Cor 30C Diluted beyond Avogadro's Limit Combats Skin Papilloma in Mice Evid. Based Complement. Altern. Med., July 16, 2009; (2009) nep084v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Bass, P. Sienkiewicz, C. J. MacDonald, R. Y.S. Cheng, A. Sparatore, P. Del Soldato, D. D. Roberts, T. W. Moody, D. A. Wink, and G. C. Yeh Novel Dithiolethione-Modified Nonsteroidal Anti-Inflammatory Drugs in Human Hepatoma HepG2 and Colon LS180 Cells Clin. Cancer Res., March 15, 2009; 15(6): 1964 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. Pokharel, E. H. Han, J. Y. Kim, S. J. Oh, S. K. Kim, E.-R. Woo, H. G. Jeong, and K. W. Kang Potent protective effect of isoimperatorin against aflatoxin B1-inducible cytotoxicity in H4IIE cells: bifunctional effects on glutathione S-transferase and CYP1A Carcinogenesis, December 1, 2006; 27(12): 2483 - 2490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Ciolino, C. J. MacDonald, O. S. Memon, S. E. Bass, and G. C. Yeh Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro Carcinogenesis, August 1, 2006; 27(8): 1586 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), 1 (
), 2 (
), or 5 mM salicylamide (SAL; 
), or 10 µM unlabeled TCDD (
) for 2 h at 4°C. The specific binding was measured by sucrose density gradient centrifugation. Results are representative of two separate experiments.